BOULDER,
Colo., Nov. 7, 2024 /PRNewswire/ -- Enliven
Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a
clinical-stage biopharmaceutical company focused on the discovery
and development of small molecule therapeutics, today announced
that management will participate in a fireside chat at the
Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 9:30 a.m. GMT.
The fireside chat will be webcast live and can be accessed by
visiting the investor relations section of the Company's website at
https://ir.enliventherapeutics.com/. The webcast will be archived
for a period of 90 days following the conclusion of the live
event.
About Enliven
Enliven is a clinical-stage
biopharmaceutical company focused on the discovery and development
of small molecule therapeutics to help people with cancer not only
live longer, but live better. Enliven aims to address existing and
emerging unmet needs with a precision oncology approach that
improves survival and enhances overall well-being. Enliven's
discovery process combines deep insights in clinically validated
biological targets and differentiated chemistry to design
potentially first-in-class or best-in-class therapies. Enliven is
based in Boulder, Colorado.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/enliven-therapeutics-to-present-at-the-jefferies-london-healthcare-conference-302299207.html
SOURCE Enliven Therapeutics, Inc.
